Quote from VigiServe Admin on January 31, 2026, 7:58 AM

The Pharmacovigilance system in Qatar is overseen by the Ministry of Public Health (MoPH) through the Pharmacy and Drug Control Department (PDCD). The framework is functional but leaner than strictly regulated GCC neighbors like Saudi Arabia or Kuwait. It relies heavily on GCC centralized registration, Arab GVP guidelines (Version 3, 2015), and WHO principles rather than a standalone national guideline.

1. Clinical Safety (Clinical Trials)

Safety monitoring during trials requires MoPH/PDCD and ethics committee approval. The system aligns with ICH E2A and WHO norms.

• Expedited Reporting: Sponsors must report Suspected Unexpected Serious Adverse Reactions (SUSARs) quickly. While not codified in a rigid national law, the expectation follows international standards:

  • 7 days for fatal or life-threatening cases.

  • 15 days for other serious unexpected reactions.

• Periodic Reporting: Sponsors may be required to submit Development Safety Update Reports (DSURs) or annual safety updates (ICH E2F format), particularly for ongoing trials.

• Oversight: Sponsors are responsible for causality assessment and communicating safety data to authorities and ethics committees. There is no dedicated electronic portal (e.g., EudraVigilance); submissions are typically via email or paper forms.

2. Post-Marketing Pharmacovigilance

Post-approval surveillance focuses on voluntary reporting and national coordination rather than complex industry obligations.

• Governance: Qatar is an associate member of the WHO Programme for International Drug Monitoring. There is no independent national Pharmacovigilance center; data is handled directly within the PDCD.

• Personnel & Infrastructure:

  • No mandatory local QPPV: Unlike other GCC markets, there is no explicit requirement for a local Qualified Person for Pharmacovigilance residing in Qatar.

  • No PSMF Mandate: Registration or location of a Pharmacovigilance System Master File in Qatar is not required.

• Incident Reporting (ICSRs):

  • Marketing Authorization Holders (MAHs) and healthcare professionals report suspected adverse drug reactions (ADRs), quality defects, or lack of efficacy.

  • Timelines: "Prompt" reporting is required for serious or unexpected events (generally interpreted as 15 days).

• Periodic & Risk Reporting:

  • PSURs/PBRERs: Not routinely mandatory for all products. Updates may be requested during renewal or variation.

  • Risk Management Plans (RMPs): Not a standard requirement, though MoPH may request them for new substances, biologics, or high-risk drugs.

Summary of Requirements

Component	Requirement in Qatar
Regulatory Authority	Ministry of Public Health (MoPH) – Pharmacy & Drug Control Dept.
Guideline Reference	Arab GVP (v3, 2015), WHO, and GCC Centralized Rules.
Local QPPV	Not required.
PSMF Location	Not required in Qatar.
SUSAR Reporting	Expedited (typically 7–15 days); submitted via email/form.
RMPs & PSURs	On request only (usually for high-risk/new drugs).